Weight
Semaglutide
Weekly injection
Weight management
Compounded Tirzepatide
Dual GIP/GLP-1 action for appetite and metabolic control.
Medical guidance
Clinical review required
Availability and treatment are not guaranteed.
vidameds
Compounded medications are not FDA-approved.
Understanding Tirzepatide
Know the treatment.
Ask better questions.
Tirzepatide acts on GIP and GLP-1 receptors. Approved formulations have specific diabetes or weight-management indications; the compounded product shown here is not FDA-approved.
How it works
Its dual receptor activity influences appetite and blood sugar regulation. Medical review and supportive lifestyle changes are important parts of treatment.
Safety & suitability
Digestive side effects are common. Serious risks and contraindications require review, including pancreatitis, gallbladder disease, and certain thyroid cancer histories. It can affect oral contraceptive effectiveness when starting or increasing doses.
Bring to your care conversation
- How do my medical history and other medicines affect the choice of treatment?
- What is the exact formulation, and which approved alternatives should I consider?
- What side effects, interactions, and follow-up should we discuss before a decision?
Research, in perspective
What the evidence says.
Dual-receptor biology. Measured clinical outcomes.
SURMOUNT-1 studied adults with obesity, or overweight with a weight-related complication, without diabetes. At 72 weeks, average weight reduction was 15.0%, 19.5%, and 20.9% in the 5, 10, and 15 mg groups, versus 3.1% with placebo.
The visual shows the 15 mg group, not an expected result or a dose recommendation. This study did not evaluate the compounded product pictured here. SURMOUNT-1 and STEP-1 are separate trials and should not be treated as a head-to-head comparison.
Read the sourcesSURMOUNT-1 · 2022
Average body-weight reduction
Adults with obesity or overweight plus a weight-related complication, without diabetes.
2,539 participants72 weeks
0–25% scale · Both groups received lifestyle support
01
GIP and GLP-1 receptor activity
02
Appetite and blood-glucose regulation
03
Response depends on the person, formulation, and follow-up
Sources & further reading
- 01SURMOUNT-1: Tirzepatide once weekly for the treatment of obesity (2022)
- 02FDA: Concerns with unapproved GLP-1 drugs used for weight loss
Research context is educational and does not confirm the safety, effectiveness, or availability of the pictured product.
The Vida Meds difference
Connected care.
Personal at every step.
A nationwide provider network. Direct pharmacy pricing. A team you can reach.
200+
Licensed providers
A nationwide network of licensed clinicians.
50 states
Nationwide care
Our provider network spans all 50 states.
Direct pharmacy
Pricing
Direct Pharmacy Pricing for your treatment.
Overnight
ColdChain Shipping
Temperature-controlled shipping for medications that require it.
24-hour
Customer support
Support for your questions, around the clock.
Direct access
Patient portal
Connect with your provider and dedicated care team.
Treatment eligibility, medication availability, and shipping arrangements depend on clinical review and the prescribed medication. Customer support is not emergency care; call 911 for a medical emergency.
Beyond the medication
A healthier weight. A fuller life.
Explore GLP-1 treatment alongside nutrition, movement, and medical guidance. The right approach starts with your health history—not a one-size-fits-all plan.
Explore weight management
